JP2024510757A - 炎症細胞または活性化細胞を標的とし、炎症性の状態および疼痛を処置するかまたは改善するための組成物および方法 - Google Patents

炎症細胞または活性化細胞を標的とし、炎症性の状態および疼痛を処置するかまたは改善するための組成物および方法 Download PDF

Info

Publication number
JP2024510757A
JP2024510757A JP2023557027A JP2023557027A JP2024510757A JP 2024510757 A JP2024510757 A JP 2024510757A JP 2023557027 A JP2023557027 A JP 2023557027A JP 2023557027 A JP2023557027 A JP 2023557027A JP 2024510757 A JP2024510757 A JP 2024510757A
Authority
JP
Japan
Prior art keywords
aibp
amino acid
virus
acid sequence
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023557027A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024510757A5 (enExample
Inventor
ユーリー ミラー，
ス－ホ チェ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California, San Diego
Original Assignee
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, San Diego filed Critical University of California, San Diego
Publication of JP2024510757A publication Critical patent/JP2024510757A/ja
Publication of JP2024510757A5 publication Critical patent/JP2024510757A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/52—Isomerases (5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y501/00—Racemaces and epimerases (5.1)
    • C12Y501/99—Racemaces and epimerases (5.1) acting on other compounds (5.1.99)
    • C12Y501/99006—NAD(P)H-hydrate epimerase (5.1.99.6)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023557027A 2021-03-18 2022-03-18 炎症細胞または活性化細胞を標的とし、炎症性の状態および疼痛を処置するかまたは改善するための組成物および方法 Pending JP2024510757A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163162714P 2021-03-18 2021-03-18
US63/162,714 2021-03-18
PCT/US2022/020991 WO2022198073A1 (en) 2021-03-18 2022-03-18 Compositions and methods for targeting inflammatory or arctivated cells and treating or ameliorating inflammatory conditions and pain

Publications (2)

Publication Number Publication Date
JP2024510757A true JP2024510757A (ja) 2024-03-11
JP2024510757A5 JP2024510757A5 (enExample) 2025-04-04

Family

ID=83321214

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023557027A Pending JP2024510757A (ja) 2021-03-18 2022-03-18 炎症細胞または活性化細胞を標的とし、炎症性の状態および疼痛を処置するかまたは改善するための組成物および方法

Country Status (10)

Country Link
US (1) US20240209341A1 (enExample)
EP (1) EP4308233A4 (enExample)
JP (1) JP2024510757A (enExample)
KR (1) KR20230159847A (enExample)
CN (1) CN117083381A (enExample)
AU (1) AU2022238450A1 (enExample)
CA (1) CA3212101A1 (enExample)
IL (1) IL305955A (enExample)
MX (1) MX2023010412A (enExample)
WO (1) WO2022198073A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022046919A2 (en) * 2020-08-25 2022-03-03 The Regents Of The University Of California Compositions and methods for the treatment of ocular neuroinflammation
EP4788360A1 (en) * 2023-10-03 2026-08-12 Raft Pharmaceuticals, Inc. Compositions and methods for treating pain disorders
WO2026006723A1 (en) * 2024-06-27 2026-01-02 Anand Rene Reagents and methods for treating headache and migraine pain and co-morbidities thereof
CN121490288A (zh) * 2025-11-21 2026-02-10 中山大学附属第三医院 一种用于急性呼吸窘迫综合征的肺部交感神经局部光遗传激活系统及方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200390906A1 (en) * 2015-12-10 2020-12-17 The Regents Of The University Of California Compositions and methods for treating or ameliorating neuroinflammation, neurodegeneration, neuropathic pain, and migraine

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8513702D0 (en) 1985-05-30 1985-07-03 Gill S S Expansible trocar
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US5846743A (en) 1995-02-22 1998-12-08 Brigham And Women's Hospital, Inc. Polyphoshoinositide binding peptides for intracellular drug delivery
US5874268A (en) 1996-09-23 1999-02-23 Duke University Method of introducing exogenous compounds into cells by electroporation and apparatus for same
SE9704076D0 (sv) 1997-11-06 1997-11-06 Holdingbolaget Vid Goeteborgs Method for permeabilisation of cell structures and use thereof
US6589503B1 (en) 1998-06-20 2003-07-08 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US20030181366A1 (en) * 2002-03-21 2003-09-25 Yan Luo Peptide inhibitors of Akt and uses thereof
US7343205B1 (en) 2002-08-20 2008-03-11 Boston Scientific Neuromodulation Corp. System and method for insertion of a device into the brain
EP1551292B1 (en) 2002-09-24 2016-04-27 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Imaging method for convection enhanced delivery of therapeutic agents
US20050142141A1 (en) 2002-11-27 2005-06-30 Pardridge William M. Delivery of enzymes to the brain
US20040151766A1 (en) 2003-01-30 2004-08-05 Monahan Sean D. Protein and peptide delivery to mammalian cells in vitro
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
WO2005063156A1 (en) 2003-12-22 2005-07-14 Shear/Kershman Laboratories, Inc. Oral peptide delivery system with improved bioavailability
KR20060123384A (ko) 2003-12-24 2006-12-01 가부시키가이샤 엘티티 바이오파마 약물을 함유하는 나노 입자 및 그 제조 방법, 그리고 당해나노 입자로 이루어지는 비경구 투여용 제제
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
US20070082042A1 (en) 2004-08-06 2007-04-12 Deok-Hoon Park Multiple-layered liposome and preparation method thereof
EP1812074B1 (en) 2004-10-18 2010-12-29 Nitto Denko Corporation Intracellular peptide delivery
US20060129126A1 (en) 2004-11-19 2006-06-15 Kaplitt Michael G Infusion device and method for infusing material into the brain of a patient
JP5639338B2 (ja) 2005-07-27 2014-12-10 プロチバ バイオセラピューティクス インコーポレイティッド リポソームの製造システムおよび製造方法
US20080132878A1 (en) 2006-11-30 2008-06-05 Douglas Kondziolka Device for cell delivery into the brain or body
US8419710B2 (en) 2006-12-06 2013-04-16 Medtronic, Inc. Methods for infusing fluids via an implantable infusion system
US10364275B2 (en) * 2013-05-27 2019-07-30 The Regents Of The University Of California Methods for treating inflammatory responses or diseases caused by inflammation using ApoA-I binding protein (APOA1BP)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200390906A1 (en) * 2015-12-10 2020-12-17 The Regents Of The University Of California Compositions and methods for treating or ameliorating neuroinflammation, neurodegeneration, neuropathic pain, and migraine

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"pAcHLT-A, B, C", BD BACULOGOLD(TM) BACULOVIRUS EXPRESSION SYSTEM INNOVATIVE SOLUTIONS FOR PROTEOMICS, JPN6026005851, 6 February 2026 (2026-02-06), pages 15, ISSN: 0005795536 *
CELL REPORTS, vol. 23, JPN6026005850, 2018, pages 2667 - 2677, ISSN: 0005795537 *
JOURNAL OF LIPID RESEARCH, vol. 59, JPN6026005849, 2018, pages 854 - 863, ISSN: 0005795538 *
REDOX BIOLOGY, vol. 37, 101703, JPN6026005848, 2020, pages 1 - 19, ISSN: 0005795539 *

Also Published As

Publication number Publication date
EP4308233A1 (en) 2024-01-24
AU2022238450A1 (en) 2023-11-02
MX2023010412A (es) 2024-01-25
CN117083381A (zh) 2023-11-17
WO2022198073A1 (en) 2022-09-22
EP4308233A4 (en) 2025-08-13
KR20230159847A (ko) 2023-11-22
US20240209341A1 (en) 2024-06-27
CA3212101A1 (en) 2022-09-22
AU2022238450A9 (en) 2023-11-16
IL305955A (en) 2023-11-01

Similar Documents

Publication Publication Date Title
US20240209341A1 (en) Compositions and methods for targeting inflammatory or activated cells and treating or ameliorating inflammatory conditions and pain
US12208143B2 (en) Compositions and methods for transport across the blood brain barrier
US11478556B2 (en) Compositions and methods for treating or ameliorating neuroinflammation, neurodegeneration, neuropathic pain, and migraine
US20250270547A1 (en) Trans-splicing ribozyme specific to apoe4 rna and use thereof
WO2019183246A1 (en) Compositions and methods of fas inhibition
US20250186546A1 (en) Compositions and Methods to Prevent, Inhibit or Treat Autoimmune and Vascular Disease
US11801284B2 (en) Compositions and methods for treating motor neuron diseases
US20210121539A1 (en) Methods and compositions for modulating myeloperoxidase (mpo) expression
WO2024186639A2 (en) Butyrophilin a2 and related isoforms for the treatment of autoimmunity and inflammation
AU2023329830A1 (en) Engineered constructs for increased transcription of rna payloads
CA3190597A1 (en) Compositions and methods for the treatment of ocular neuroinflammation
WO2024115767A1 (en) Nomacopan-pas fusion proteins
HK40055788A (en) Compositions and methods for transport across the blood brain barrier
CN116159126A (zh) 同源二聚体介导的C/EBPαS16磷酸化通过液-液相分离调节急性髓系白血病分化
CN110913884A (zh) 抑制dna依赖蛋白激酶催化亚基的药物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250318

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250318

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260213

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260522

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260804